Floatz logo

ABATACEPT RECOMBINANT

Alzheimer Disease

Massachusetts General Hospitalprotein_peptidePhase 1/2Active
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
65/ 100

Competitive context

203 Active assets in the Alzheimer Disease cohort.

Asset / SponsorPhaseRating
FLORTAUCIPIR
Eli Radiopharma
Phase 4BBB
Galantamine Hydrobromide
Janssen Cilag Pharmaceutica S.A.C.I., Greece
Phase 4BBB
Florbetaben
National Institute of Mental Health (NIMH)
Phase 4BBB
Donanemab
Michael Rafii, MD, PhD
Phase 4BB
AMILOMOTIDE
Novartis Pharmaceuticals
Phase 2/3BB

View all 50 →

Same molecule, other indications

ABATACEPT RECOMBINANT is also rated in:

Primary Biliary CholangitisDormant
BB
Indicative ·
69 / 100
View asset →
acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
primary biliary cholangitisDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →